Singapore markets closed
Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,809.48 -1,613.76 (-2.59%) CMC Crypto 200
1,258.80 -99.21 (-7.31%)
Gilead Sciences, Inc. (0QYQ.IL)
IOB - IOB Delayed price. Currency in USD
Add to watchlist
At close: 07:14PM BST
| Previous close | 65.04 |
| Open | 65.02 |
| Bid | 62.77 x N/A |
| Ask | 69.33 x N/A |
| Day's range | 64.50 - 66.19 |
| 52-week range | 64.38 - 87.53 |
| Volume | |
| Avg. volume | 50,625 |
| Market cap | 82.274B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | 15.18 |
| EPS (TTM) | 4.35 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | 3.00 (3.81%) |
| Ex-dividend date | 14 Sept 2023 |
| 1y target est | N/A |
ZacksGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Business WireKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
GuruFocus.comDecoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
Unraveling the Financial Dynamics and Strategic Directions of Gilead Sciences Inc (GILD)
© 2024 Yahoo. All rights reserved.